INVA
Price:
$17.76
Market Cap:
$1.11B
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group...[Read more]
Industry
Biotechnology
IPO Date
2004-10-05
Stock Exchange
NASDAQ
Ticker
INVA
According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 22.20. This represents a change of -64.80% compared to the average of 63.08 of the last 4 quarters.
The mean historical PE Ratio of Innoviva, Inc. over the last ten years is -0.95. The current 22.20 PE Ratio has changed -232749.89% with respect to the historical average. Over the past ten years (40 quarters), INVA's PE Ratio was at its highest in in the September 2024 quarter at 249.01. The PE Ratio was at its lowest in in the June 2015 quarter at -65.49.
Average
-0.95
Median
5.02
Minimum
-64.82
Maximum
19.82
Discovering the peaks and valleys of Innoviva, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 620.09%
Maximum Annual PE Ratio = 19.82
Minimum Annual Increase = -130.58%
Minimum Annual PE Ratio = -64.82
Year | PE Ratio | Change |
---|---|---|
2023 | 5.84 | 35.38% |
2022 | 4.31 | 12.40% |
2021 | 3.84 | -31.39% |
2020 | 5.59 | -38.57% |
2019 | 9.11 | 104.42% |
2018 | 4.45 | -60.62% |
2017 | 11.31 | -42.92% |
2016 | 19.82 | -130.58% |
2015 | -64.82 | 620.09% |
2014 | -9.00 | -43.81% |
The current PE Ratio of Innoviva, Inc. (INVA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
4.66
5-year avg
5.74
10-year avg
-0.95
Innoviva, Inc.’s PE Ratio is greater than eFFECTOR Therapeutics, Inc. (-0.00), greater than Protalix BioTherapeutics, Inc. (-13.63), greater than PDS Biotechnology Corporation (-1.52), greater than aTyr Pharma, Inc. (-2.33), greater than Elevation Oncology, Inc. (-0.83), greater than Day One Biopharmaceuticals, Inc. (-14.30), greater than Mirati Therapeutics, Inc. (-11.26), greater than Amylyx Pharmaceuticals, Inc. (-1.05), greater than Terns Pharmaceuticals, Inc. (-5.02), greater than Apellis Pharmaceuticals, Inc. (-16.11), greater than X4 Pharmaceuticals, Inc. (-7.43), greater than Inozyme Pharma, Inc. (-1.88), greater than HOOKIPA Pharma Inc. (-0.55), greater than Acumen Pharmaceuticals, Inc. (-1.29), greater than Amicus Therapeutics, Inc. (-28.17), less than Incyte Corporation (414.17), greater than Denali Therapeutics Inc. (-8.15), greater than argenx SE (-368.87), greater than Harmony Biosciences Holdings, Inc. (15.75),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $941.00 | |
-13.63 | $131.07M | |
-1.52 | $62.47M | |
-2.33 | $131.12M | |
-0.83 | $34.88M | |
-14.30 | $1.26B | |
-11.26 | $4.12B | |
-1.05 | $273.85M | |
-5.02 | $482.88M | |
-16.11 | $4.04B | |
-7.43 | $105.79M | |
-1.88 | $184.37M | |
-0.55 | $18.34M | |
-1.29 | $105.44M | |
-28.17 | $2.89B | |
414.17 | $13.45B | |
-8.15 | $2.96B | |
-368.87 | $37.79B | |
15.75 | $1.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Innoviva, Inc.'s PE Ratio?
How is the PE Ratio calculated for Innoviva, Inc. (INVA)?
What is the highest PE Ratio for Innoviva, Inc. (INVA)?
What is the 3-year average PE Ratio for Innoviva, Inc. (INVA)?
What is the 5-year average PE Ratio for Innoviva, Inc. (INVA)?
How does the current PE Ratio for Innoviva, Inc. (INVA) compare to its historical average?